Cargando…

A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model

The COVID-19 pandemic has generated intense interest in the rapid development and evaluation of vaccine candidates for this disease and other emerging diseases. Several novel methods for preparing vaccine candidates are currently undergoing clinical evaluation in response to the urgent need to preve...

Descripción completa

Detalles Bibliográficos
Autores principales: Ragan, Izabela K, Hartson, Lindsay M, Dutt, Taru S, Obregon-Henao, Andres, Maison, Rachel M, Gordy, Paul, Fox, Amy, Karger, Burton R, Cross, Shaun T, Kapuscinski, Marylee L, Cooper, Sarah K, Podell, Brendan K, Stenglein, Mark D, Bowen, Richard A, Henao-Tamayo, Marcela, Goodrich, Raymond P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8066708/
https://www.ncbi.nlm.nih.gov/pubmed/33916180
http://dx.doi.org/10.3390/vaccines9040340
_version_ 1783682632067842048
author Ragan, Izabela K
Hartson, Lindsay M
Dutt, Taru S
Obregon-Henao, Andres
Maison, Rachel M
Gordy, Paul
Fox, Amy
Karger, Burton R
Cross, Shaun T
Kapuscinski, Marylee L
Cooper, Sarah K
Podell, Brendan K
Stenglein, Mark D
Bowen, Richard A
Henao-Tamayo, Marcela
Goodrich, Raymond P
author_facet Ragan, Izabela K
Hartson, Lindsay M
Dutt, Taru S
Obregon-Henao, Andres
Maison, Rachel M
Gordy, Paul
Fox, Amy
Karger, Burton R
Cross, Shaun T
Kapuscinski, Marylee L
Cooper, Sarah K
Podell, Brendan K
Stenglein, Mark D
Bowen, Richard A
Henao-Tamayo, Marcela
Goodrich, Raymond P
author_sort Ragan, Izabela K
collection PubMed
description The COVID-19 pandemic has generated intense interest in the rapid development and evaluation of vaccine candidates for this disease and other emerging diseases. Several novel methods for preparing vaccine candidates are currently undergoing clinical evaluation in response to the urgent need to prevent the spread of COVID-19. In many cases, these methods rely on new approaches for vaccine production and immune stimulation. We report on the use of a novel method (SolaVAX) for production of an inactivated vaccine candidate and the testing of that candidate in a hamster animal model for its ability to prevent infection upon challenge with SARS-CoV-2 virus. The studies employed in this work included an evaluation of the levels of neutralizing antibody produced post-vaccination, levels of specific antibody sub-types to RBD and spike protein that were generated, evaluation of viral shedding post-challenge, flow cytometric and single cell sequencing data on cellular fractions and histopathological evaluation of tissues post-challenge. The results from this preliminary evaluation provide insight into the immunological responses occurring as a result of vaccination with the proposed vaccine candidate and the impact that adjuvant formulations, specifically developed to promote Th1 type immune responses, have on vaccine efficacy and protection against infection following challenge with live SARS-CoV-2. This data may have utility in the development of effective vaccine candidates broadly. Furthermore, the results of this preliminary evaluation suggest that preparation of a whole virion vaccine for COVID-19 using this specific photochemical method may have potential utility in the preparation of one such vaccine candidate.
format Online
Article
Text
id pubmed-8066708
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80667082021-04-25 A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model Ragan, Izabela K Hartson, Lindsay M Dutt, Taru S Obregon-Henao, Andres Maison, Rachel M Gordy, Paul Fox, Amy Karger, Burton R Cross, Shaun T Kapuscinski, Marylee L Cooper, Sarah K Podell, Brendan K Stenglein, Mark D Bowen, Richard A Henao-Tamayo, Marcela Goodrich, Raymond P Vaccines (Basel) Article The COVID-19 pandemic has generated intense interest in the rapid development and evaluation of vaccine candidates for this disease and other emerging diseases. Several novel methods for preparing vaccine candidates are currently undergoing clinical evaluation in response to the urgent need to prevent the spread of COVID-19. In many cases, these methods rely on new approaches for vaccine production and immune stimulation. We report on the use of a novel method (SolaVAX) for production of an inactivated vaccine candidate and the testing of that candidate in a hamster animal model for its ability to prevent infection upon challenge with SARS-CoV-2 virus. The studies employed in this work included an evaluation of the levels of neutralizing antibody produced post-vaccination, levels of specific antibody sub-types to RBD and spike protein that were generated, evaluation of viral shedding post-challenge, flow cytometric and single cell sequencing data on cellular fractions and histopathological evaluation of tissues post-challenge. The results from this preliminary evaluation provide insight into the immunological responses occurring as a result of vaccination with the proposed vaccine candidate and the impact that adjuvant formulations, specifically developed to promote Th1 type immune responses, have on vaccine efficacy and protection against infection following challenge with live SARS-CoV-2. This data may have utility in the development of effective vaccine candidates broadly. Furthermore, the results of this preliminary evaluation suggest that preparation of a whole virion vaccine for COVID-19 using this specific photochemical method may have potential utility in the preparation of one such vaccine candidate. MDPI 2021-04-01 /pmc/articles/PMC8066708/ /pubmed/33916180 http://dx.doi.org/10.3390/vaccines9040340 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ragan, Izabela K
Hartson, Lindsay M
Dutt, Taru S
Obregon-Henao, Andres
Maison, Rachel M
Gordy, Paul
Fox, Amy
Karger, Burton R
Cross, Shaun T
Kapuscinski, Marylee L
Cooper, Sarah K
Podell, Brendan K
Stenglein, Mark D
Bowen, Richard A
Henao-Tamayo, Marcela
Goodrich, Raymond P
A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model
title A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model
title_full A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model
title_fullStr A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model
title_full_unstemmed A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model
title_short A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model
title_sort whole virion vaccine for covid-19 produced via a novel inactivation method and preliminary demonstration of efficacy in an animal challenge model
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8066708/
https://www.ncbi.nlm.nih.gov/pubmed/33916180
http://dx.doi.org/10.3390/vaccines9040340
work_keys_str_mv AT raganizabelak awholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel
AT hartsonlindsaym awholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel
AT dutttarus awholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel
AT obregonhenaoandres awholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel
AT maisonrachelm awholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel
AT gordypaul awholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel
AT foxamy awholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel
AT kargerburtonr awholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel
AT crossshaunt awholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel
AT kapuscinskimaryleel awholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel
AT coopersarahk awholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel
AT podellbrendank awholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel
AT stengleinmarkd awholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel
AT bowenricharda awholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel
AT henaotamayomarcela awholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel
AT goodrichraymondp awholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel
AT raganizabelak wholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel
AT hartsonlindsaym wholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel
AT dutttarus wholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel
AT obregonhenaoandres wholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel
AT maisonrachelm wholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel
AT gordypaul wholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel
AT foxamy wholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel
AT kargerburtonr wholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel
AT crossshaunt wholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel
AT kapuscinskimaryleel wholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel
AT coopersarahk wholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel
AT podellbrendank wholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel
AT stengleinmarkd wholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel
AT bowenricharda wholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel
AT henaotamayomarcela wholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel
AT goodrichraymondp wholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel